Your shopping cart is empty!
PAY WITH
Originally a laboratory data point, PSA, Prostate Specific Antigen, has evolved over time to become much more than just a numerical value: a tool for prevention, a clinical indicator, a potential source of anxiety, a topic of scientific debate, and a starting point for decisions involving the individual, the family, the couple, and society.
Through clear and accessible language, the book guides the reader on a journey that intertwines science, clinical practice, and personal experiences.
The urological perspective helps to understand what happens after an altered PSA, while the laboratory perspective explains how a PSA value is generated, what variables can influence it, and why no data can be interpreted without context. PSA is not a verdict, nor an absolute truth: it is information that gains meaning only when placed within the biological, clinical, and personal history of each individual.
The volume also addresses highly relevant topics: new biomarkers, artificial intelligence, personalized medicine, obesity, hormones, gender identity, biochemical recurrence, public health, and prevention.
It is aimed at patients, caregivers, health professionals, researchers, students, and anyone who wants to better understand one of the most well-known and debated markers of prostate health.
Matteo Ferro is an Associate Professor of Urology at the University of Milan and a urologist specializing in uro-oncology. His clinical and scientific work is focused on early diagnosis, risk stratification, biomarkers, and precision medicine in genitourinary tumors.
Author of numerous international scientific publications, he conducts translational research in the field of urological oncology, with particular attention to the integration of clinical data, molecular markers, imaging, and new predictive tools.
Daniela Terracciano is an Associate Professor of Clinical Pathology at the University of Naples "Federico II," where she is responsible for the Laboratory Oncology Diagnostics Unit. Her scientific activity focuses on translational diagnostics, oncological and neurological biomarkers, and laboratory and precision medicine.
For years, she has been involved in markers for prostate cancer, with particular attention to PSA, its isoforms, and the integration of biomarkers with the clinical, biological, and technological context.